Last but not least, the relationship between GAS5/miR-221-3p/IRF2 and NSCLC patients’ prognosis has not been explored, and this is crucial to evaluate the potential of these molecules as biomarkers. This evidence concerns the gene IRF2 and non-small cell lung carcinoma.